-K L Nathanson Researcher Activity Profile

Research Author Detailed Information 

K L Nathanson Publication Rate By Year

K L Nathanson has published 10 paper(s) in 2007, 6 paper(s) in 2008, for a total of 16 research publications in total.

K L Kl Nathanson Author Information

LAST NAME: nathanson

FIRST NAME: K L

INITIALS: kl

AFFILIATION:

Papers

K L Nathanson's Publication Record

1. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Year Published: 2007
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA. ksmalley@wistar.org
2. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Year Published: 2007
Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA.
3. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. Year Published: 2007
Clinical Translational Medicine, Oncology, Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426, USA.
4. Network modeling links breast cancer susceptibility and centrosome dysfunction. Year Published: 2007
Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, 44 Binney St., Boston, Massachusetts 02115, USA.
5. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Year Published: 2007
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK. antonis@srl.cam.ac.uk
6. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Year Published: 2007
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK. antonis@srl.cam.ac.uk
7. Network modeling links breast cancer susceptibility and centrosome dysfunction. Year Published: 2007
Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, 44 Binney St., Boston, Massachusetts 02115, USA.
8. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Year Published: 2007
Authors' Affiliations: Human Genetics Group and Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Center (CNIO).
9. The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. Year Published: 2008
Authors' Affiliations: The Wistar Institute, Division of Medical Genetics, University of Pennsylvania School of Medicine, and Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania.
10. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Year Published: 2008
Testicular Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK.
11. Network modeling links breast cancer susceptibility and centrosome dysfunction. Year Published: 2007
Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute and Department of Genetics, Harvard Medical School, 44 Binney St., Boston, Massachusetts 02115, USA.
12. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Year Published: 2008
Testicular Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK.
13. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Year Published: 2007
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center (CNIO), Madrid, Spain.
14. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Year Published: 2008
The Wistar Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
15. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Year Published: 2008
The Wistar Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
16. Factors Determining Dissemination of Results and Uptake of Genetic Testing in Families with Known BRCA1/2 Mutations. Year Published: 2008
Division of Hematology/Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.